Counterpart Health launched a new integrated scribing solution for its CA platform, enhancing physician-patient interactions and reducing documentation burden.
Quiver AI Summary
Counterpart Health, a subsidiary of Clover Health, has announced a significant upgrade to its CA Assistant, introducing a fully integrated ambient scribing solution aimed at enhancing the physician and patient experience. This new capability allows eligible physicians to focus more on patient care rather than administrative tasks, as the AI-powered solution listens and generates real-time summaries of patient-physician interactions. It is designed to work seamlessly within the existing workflow of Counterpart's value-based care platform, enabling clinicians to manage care more efficiently while improving clinical outcomes. The feature supports multilingual conversations and is available at no cost to clinicians within Clover's network. CEO Conrad Wai emphasized the goal of integrating clinical insights directly into physicians' workflows to reduce burnout and enhance patient engagement. Overall, this launch continues to position Counterpart Health as an innovative leader in AI-driven healthcare solutions.
Potential Positives
- Launch of a fully integrated ambient scribing solution enhances the Counterpart Assistant (CA) platform, improving the efficiency of medical visits and reducing clinician administrative burdens.
- New capability available at no cost to all clinicians in the Clover Health network, demonstrating the company's commitment to empowering healthcare professionals and enhancing patient care.
- The AI-powered scribing solution aims to enhance patient-physician engagement, potentially leading to better clinical outcomes and higher patient satisfaction.
Potential Negatives
- While the release touts the benefits of the new scribing solution, it lacks specific details on the implementation timeline and potential challenges, which could raise concerns among practitioners regarding adaptability.
- The announcement does not address any competitive landscape or how the integrated scribing solution differentiates itself from existing market players, which may lead to skepticism about its effectiveness.
- There is no mention of how the new technology will be funded or any potential financial implications for Clover Health, which could concern investors about future profitability.
FAQ
What is Counterpart Assistant's new ambient scribing solution?
Counterpart Assistant now includes an integrated ambient scribing solution that enhances physician workflow and patient engagement during visits.
How does the scribing solution improve physician efficiency?
The ambient scribing solution reduces documentation burdens, allowing physicians to focus more on patient care rather than administrative tasks.
Is the scribing solution available to all physicians?
Yes, Clover Health provides the ambient scribing capability at no cost to all eligible physicians using Counterpart Assistant.
What technology powers the ambient scribing solution?
The scribing solution is powered by advanced AI, which listens, learns, and generates summaries in real time during patient visits.
How does the integrated solution benefit patient care?
By streamlining documentation, the solution fosters more engaged patient visits and strengthens the relationship between physicians and their patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLOV Insider Trading Activity
$CLOV insiders have traded $CLOV stock on the open market 10 times in the past 6 months. Of those trades, 4 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
- CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 4 sales selling 49,074 shares for an estimated $134,995.
- ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLOV Hedge Fund Activity
We have seen 119 institutional investors add shares of $CLOV stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 20,029,317 shares (+193.2%) to their portfolio in Q2 2025, for an estimated $55,881,794
- GEODE CAPITAL MANAGEMENT, LLC added 4,812,368 shares (+95.7%) to their portfolio in Q2 2025, for an estimated $13,426,506
- MILLENNIUM MANAGEMENT LLC removed 4,745,791 shares (-81.8%) from their portfolio in Q2 2025, for an estimated $13,240,756
- STATE STREET CORP added 4,580,664 shares (+156.5%) to their portfolio in Q2 2025, for an estimated $12,780,052
- VANGUARD GROUP INC added 3,665,917 shares (+17.8%) to their portfolio in Q2 2025, for an estimated $10,227,908
- BANK OF AMERICA CORP /DE/ added 2,748,783 shares (+217.5%) to their portfolio in Q2 2025, for an estimated $7,669,104
- NORTHERN TRUST CORP added 2,341,788 shares (+226.4%) to their portfolio in Q2 2025, for an estimated $6,533,588
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.
$CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.55.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $4.1 on 08/07/2025
- Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025
Full Release
SAN FRANCISCO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI‑powered physician‑enablement platform, today announced a major upgrade to Counterpart Assistant (CA): the launch of its fully integrated ambient scribing solution. With this release, CA just got smarter, turning every visit into a seamless, conversational experience that delivers better care with less effort. The capability will be available to all eligible physicians using CA, bringing enterprise-grade technology to every practice, including small independent offices where such tools are often out of reach.
Unlike standalone scribing tools, CA’s integrated solution is embedded directly into its value-based care platform, extending the same workflow that already empowers early diagnosis, care gap closure, and better clinical outcomes. Scribing alone is helpful in reducing documentation burden, but CA’s integrated solution goes further, strengthening CA’s ability to support clinicians in producing high-quality care outcomes.
CA’s scribing solution listens, learns, and works in real time. Powered by advanced AI, it generates a summary of available audio, surfaces insights in real time, and integrates seamlessly into the visit workflow. Physicians stay focused on patients, not administrative burden; patients benefit from more engaged visits and stronger relationships with their physicians. The desktop- and mobile-optimized experience supports multilingual conversations, letting clinicians use their phone, tablet, or computer microphone to capture visit dialogue and deliver patient-centered care in any setting.
“Our goal has always been to deliver clinical insights directly into the physician’s workflow, supporting better care and making every encounter more seamless,” said Conrad Wai, CEO of Counterpart Health. “By bringing scribing into value-based care, we are enabling clinicians to focus on managing care, rather than keeping up with documentation.”
Clover Health is providing this new capability at no cost to all clinicians using CA within its network, underscoring the company’s commitment to empowering physicians and elevating patient care.
“As an independent PCP, balancing patient care with extensive documentation demands is a daily challenge,” said Dr. Quinones, a Family Medicine doctor and early adopter of CA’s scribing solution. “The ambient scribe integrated into CA has tremendously saved me time, reduced my documentation burden, and diminished feelings of burnout. It allows me to focus more on what matters most — my patients."
The launch of CA scribing is part of a continuing wave of next-generation AI features that further enhance the physician experience and value-based care, setting a new standard for how clinicians and technology work together to deliver better care and continuing to prove that technology should work for physicians, not the other way around.
About Counterpart Health
Counterpart Health , a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes , Chronic Kidney Disease , Congestive Heart Failure , and Chronic Obstructive Pulmonary Disease management, and Clinical Quality .
Investor Relations:
Ryan Schmidt
Press Inquiries: